SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSMD.L Regulatory News (SMD)

  • There is currently no data for SMD

Total Voting Rights

3 Feb 2023 16:24

RNS Number : 9261O
Spectral MD Holdings, Ltd.
03 February 2023
 

3 February 2023

Spectral MD Holdings, Ltd.

("Spectral MD" or the "Company")

 

Total Voting Rights

 

LONDON, U.K. AND DALLAS, TX, U.S. - Spectral MD Holdings, Ltd. (AIM: SMD), a predictive analytics company with proprietary AI algorithms and optical technology for faster and more accurate treatment decisions in wound care, announces that, as at the date of this announcement, there are 136,201,515 ordinary shares of Common Stock of US $0.001 each ("Shares") in issue, with one voting right per Share. This follows the issue of 104,451 Shares in January in satisfaction of option exercises and in accordance with the Company's block listing, details of which were announced on 7 November 2022.

 

The total number of voting rights in the Company is therefore 136,201,515.

 

This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the issued share capital of the Company under the Company's Certificate of Incorporation. No Common Stock is held in treasury.

 

 

 

 

For further information please contact:

 

Spectral MD Holdings, Ltd.

investors.spectralmd.com

Wensheng Fan, Chief Executive Officer

via Walbrook PR

Nils Windler, Chief Financial Officer

 

 

 

SP Angel Corporate Finance LLP (NOMAD and Joint Broker)

Tel: +44 (0)20 3470 0470

Stuart Gledhill/Harry Davies-Ball (Corporate Finance)

Vadim Alexandre/Rob Rees (Sales & Broking)

 

 

 

 

Stifel Nicolaus Europe Limited (Joint Broker)

Charles Hoare / Ben Maddison / Nick Harland

Will Palmer-Brown

Tel: +44 (0)20 7710 7600

 

 

Walbrook PR Ltd (Media & Investor Relations)

Tel: +44 (0)20 7933 8780 or spectralMD@walbrookpr.com

Paul McManus / Louis Ashe-Jepson /

Sam Allen

Mob: +44 (0)7980 541 893 / +44 (0)7747 515 393

+44 (0)7502 558 258

 

About Spectral MD:

We are a dedicated team of forward-thinkers striving to revolutionize the management of wound care by "Seeing the Unknown" ® with our DeepView® Wound Imaging System.

www.spectralmd.com

info@spectralmd.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TVREAKADEAFDEFA
12
Date   Source Headline
10th May 20227:00 amRNSPublication of Annual Financial Report
13th Apr 20227:00 amRNSAppointment: V.P of Marketing
21st Mar 20227:00 amRNSFinal Results
9th Mar 20227:00 amRNSNotice of Full Year Results
4th Feb 20227:00 amRNSGrant of share options and cash bonus
1st Feb 20227:00 amRNSTrading Update and Notice of Results
11th Jan 20227:00 amRNSDirector/PDMR Shareholding
23rd Dec 20213:13 pmRNSShare Dealing and Exercise of Options
21st Dec 20217:00 amRNSGrant of share options and Management update
1st Dec 20217:00 amRNSAppointment of CFO
18th Nov 20217:00 amRNSEnrolment Completed for DFU Training Study
16th Nov 20217:00 amRNSClinical results presented at US Burn Conference
20th Oct 20217:00 amRNSAppointment of Joint Broker
11th Oct 20212:00 pmRNSGrant of share options
13th Sep 20217:00 amRNSHalf-year Report
7th Sep 20217:00 amRNSNotice of Results
9th Aug 20217:00 amRNSKick-off event to launch clinical study
15th Jul 20217:00 amRNSHolding(s) in Company
24th Jun 20217:00 amRNSContract Award from US Department of Defense
22nd Jun 20217:00 amRNSAdmission to trading on AIM; First Day of Dealings
12

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.